The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.
Resource
J. Clin. Oncol., 33(15),
Journal
J. Clin. Oncol.
Journal Volume
33
Journal Issue
15
Pages
-
Date Issued
2015
Date
2015
Author(s)
Lee, Chee
Davies, Lucy Claire
Wu, Yi-Long
Mitsudomi, Tetsuya
Inoue, Akira
Rosell, Rafael
Zhou, Caicun
Nakagawa, Kazuhiko
Throngprasert, Sumitra
Fukuoka, Masahiro
Gralla, Richard J.
Gebski, Val
Mok, Tony
Yang, James Chih-Hsin
SDGs